AC Immune
Lausanne
About AC Immune
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with three product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune's two proprietary technology platforms create antibodies, small molecules and vaccines to address a broad spectrum of neurodegenerative indications
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $167.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2023)
- Ticker: nasdaq:ACIU
- Website: acimmune.com
- Phone: +41 21 345 91 21
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ac-immune-24349 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.